{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,21]],"date-time":"2026-11-21T22:37:11Z","timestamp":1795300631276,"version":"4.10.3"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["GR2018\\u2013032"],"award-info":[{"award-number":["GR2018\\u2013032"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","award":["A20\\u2013035"],"award-info":[{"award-number":["A20\\u2013035"]}],"id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.drugalcdep.2025.113014","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T15:49:41Z","timestamp":1767109781000},"page":"113014","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Successful hepatitis C elimination through decentralized treatment in Dutch addiction care: A RE-AIM based evaluation"],"prefix":"10.1016","volume":"279","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4567-2391","authenticated-orcid":false,"given":"Daan W.","family":"Von den Hoff","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Floor A.C.","family":"Berden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie","family":"Noordeloos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Knuijver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7715-5209","authenticated-orcid":false,"given":"Arnt F.A.","family":"Schellekens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost P.H.","family":"Drenth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2025.113014_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108526","article-title":"Patients at a drug detoxification center share perspectives on how to increase hepatitis C treatment uptake: a qualitative study","volume":"220","author":"Assoumou","year":"2021","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"10.1016\/j.drugalcdep.2025.113014_bib2","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12954-024-01057-z","article-title":"Subspecialty physicians' perspectives on barriers and facilitators of hepatitis C treatment: a qualitative study","volume":"21","author":"Bredenberg","year":"2024","journal-title":"Harm Reduct. J."},{"key":"10.1016\/j.drugalcdep.2025.113014_bib3","doi-asserted-by":"crossref","first-page":"w20460","DOI":"10.4414\/smw.2021.20460","article-title":"Hepatitis C virus elimination in Swiss opioid agonist therapy programmes - the SAMMSU cohort","volume":"151","author":"Bregenzer","year":"2021","journal-title":"Swiss Med. Wkly."},{"issue":"1","key":"10.1016\/j.drugalcdep.2025.113014_bib4","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1186\/s12889-021-11608-9","article-title":"On-site testing and case management to improve hepatitis C care in drug users: a prospective, longitudinal, multicenter study in the DAA era","volume":"21","author":"Busschots","year":"2021","journal-title":"BMC Public Health"},{"issue":"5","key":"10.1016\/j.drugalcdep.2025.113014_bib5","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S2468-1253(21)00471-4","article-title":"Interventions to enhance testing, linkage to care, and treatment initiation for hepatitis C virus infection: a systematic review and meta-analysis","volume":"7","author":"Cunningham","year":"2022","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"6","key":"10.1016\/j.drugalcdep.2025.113014_bib6","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jhep.2019.07.006","article-title":"Decentralized care with generic direct-acting antivirals in the management of chronic hepatitis C in a public health care setting","volume":"71","author":"Dhiman","year":"2019","journal-title":"J. Hepatol."},{"issue":"19","key":"10.1016\/j.drugalcdep.2025.113014_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10194562","article-title":"The Netherlands is on track to meet the world health organization hepatitis C elimination targets by 2030","volume":"10","author":"van Dijk","year":"2021","journal-title":"J. Clin. Med."},{"issue":"12","key":"10.1016\/j.drugalcdep.2025.113014_bib8","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1111\/jvh.13399","article-title":"Loss to follow-up in the hepatitis C care cascade: A substantial problem but opportunity for micro-elimination","volume":"27","author":"van Dijk","year":"2020","journal-title":"J. Viral Hepat."},{"issue":"5","key":"10.1016\/j.drugalcdep.2025.113014_bib9","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"EASL recommendations on treatment of hepatitis C: Final update of the series(.)","volume":"73","author":"EASL","year":"2020","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.drugalcdep.2025.113014_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003653","article-title":"Integrated treatment of hepatitis C virus infection among people who inject drugs: a multicenter randomized controlled trial (INTRO-HCV)","volume":"18","author":"Fadnes","year":"2021","journal-title":"PLOS Med."},{"issue":"1","key":"10.1016\/j.drugalcdep.2025.113014_bib11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev-med-050223-111239","article-title":"Global elimination of hepatitis C virus","volume":"76","author":"Fleurence","year":"2025","journal-title":"Annu Rev. Med."},{"issue":"3","key":"10.1016\/j.drugalcdep.2025.113014_bib12","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/liv.14779","article-title":"Progress towards hepatitis C virus elimination in high-income countries: an updated analysis","volume":"41","author":"Gamkrelidze","year":"2021","journal-title":"Liver Int."},{"issue":"2","key":"10.1016\/j.drugalcdep.2025.113014_bib13","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/hep.31060","article-title":"Hepatitis C guidance 2019 update: American association for the study of liver diseases-infectious diseases society of America recommendations for testing, managing, and treating hepatitis C virus infection","volume":"71","author":"Ghany","year":"2020","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.drugalcdep.2025.113014_bib14","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1177\/02537176221086013","article-title":"Multidisciplinary and integrated treatment for substance use disorders and hepatitis C in an addiction treatment service in India","volume":"45","author":"Ghosh","year":"2023","journal-title":"Indian J. Psychol. Med."},{"key":"10.1016\/j.drugalcdep.2025.113014_bib15","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3389\/fpubh.2019.00064","article-title":"RE-AIM planning and evaluation framework: adapting to new science and practice with a 20-year review","volume":"7","author":"Glasgow","year":"2019","journal-title":"Front. Public Health"},{"issue":"1-2","key":"10.1016\/j.drugalcdep.2025.113014_bib16","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.drugalcdep.2007.09.008","article-title":"Barriers associated with the treatment of hepatitis C virus infection among illicit drug users","volume":"93","author":"Grebely","year":"2008","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"10.1016\/j.drugalcdep.2025.113014_bib17","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12954-023-00780-3","article-title":"Assessing feasibility of a modified same-day test-and-treat model for hepatitis C among rural people who inject drugs","volume":"20","author":"Hassan","year":"2023","journal-title":"Harm. Reduct. J."},{"key":"10.1016\/j.drugalcdep.2025.113014_bib18","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.drugpo.2017.07.022","article-title":"Effectiveness and cost-effectiveness of nationwide campaigns for awareness and case finding of hepatitis C targeted at people who inject drugs and the general population in the Netherlands","volume":"47","author":"Helsper","year":"2017","journal-title":"Int. J. Drug Policy"},{"issue":"1","key":"10.1016\/j.drugalcdep.2025.113014_bib19","article-title":"Understanding and applying the RE-AIM framework: Clarifications and resources","volume":"5","author":"Holtrop","year":"2021","journal-title":"J. Clin. Transl. Sci."},{"issue":"12","key":"10.1016\/j.drugalcdep.2025.113014_bib20","first-page":"900","article-title":"Under the watchful eye of 'a benevolent dictator' - general practitioner and patient experiences of hepatitis C treatment initiation and shared-care in general practice","volume":"42","author":"Hopwood","year":"2013","journal-title":"Aust. Fam. Physician"},{"key":"10.1016\/j.drugalcdep.2025.113014_bib21","doi-asserted-by":"crossref","DOI":"10.1017\/S0950268819000359","article-title":"Chronic hepatitis B and C infections in the Netherlands: estimated prevalence in risk groups and the general population","volume":"147","author":"Koopsen","year":"2019","journal-title":"Epidemiol. Infect."},{"key":"10.1016\/j.drugalcdep.2025.113014_bib22","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s41124-018-0040-9","article-title":"Strategies for achieving viral hepatitis C micro-elimination in the Netherlands","volume":"3","author":"Kracht","year":"2018","journal-title":"Hepatol. Med. Policy"},{"issue":"1","key":"10.1016\/j.drugalcdep.2025.113014_bib23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12954-019-0316-4","article-title":"Introducing hepatitis C virus healthcare pathways in addiction care in the Netherlands with a Breakthrough project: a mixed method study","volume":"16","author":"Kracht","year":"2019","journal-title":"Harm. Reduct. J."},{"key":"10.1016\/j.drugalcdep.2025.113014_bib24","doi-asserted-by":"crossref","first-page":"g5392","DOI":"10.1136\/bmj.g5392","article-title":"Effectiveness of integrated disease management for primary care chronic obstructive pulmonary disease patients: results of cluster randomised trial","volume":"349","author":"Kruis","year":"2014","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.drugalcdep.2025.113014_bib25","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1111\/jvh.13119","article-title":"Perceived barriers related to testing, management and treatment of HCV infection among physicians prescribing opioid agonist therapy: The C-SCOPE Study","volume":"26","author":"Litwin","year":"2019","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.drugalcdep.2025.113014_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2019.107705","article-title":"Barriers and facilitators to engaging in hepatitis C management and DAA therapy among general practitioners and drug and alcohol specialists-The practitioner experience","volume":"206","author":"Marshall","year":"2020","journal-title":"Drug Alcohol Depend."},{"issue":"1","key":"10.1016\/j.drugalcdep.2025.113014_bib27","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s12954-024-01115-6","article-title":"How far are we? Assessing progress in hepatitis C response towards the WHO 2030 elimination goals by the civil society monitoring in 25 European countries, period 2020\u20132023","volume":"21","author":"Maticic","year":"2024","journal-title":"Harm. Reduct. J."},{"issue":"1","key":"10.1016\/j.drugalcdep.2025.113014_bib28","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12954-019-0314-6","article-title":"HCV treatment access among Latinxs who inject drugs: qualitative findings from Boston, Massachusetts, 2016","volume":"16","author":"Mittal","year":"2019","journal-title":"Harm. Reduct. J."},{"key":"10.1016\/j.drugalcdep.2025.113014_bib29","series-title":"Opiaten 5.6 Hulpvraag en incidenten - Nationale Drug Monitor","author":"Nationale Drug Monitor","year":"2022"},{"issue":"4","key":"10.1016\/j.drugalcdep.2025.113014_bib30","doi-asserted-by":"crossref","first-page":"e431","DOI":"10.1016\/S2214-109X(20)30505-2","article-title":"Decentralisation, integration, and task-shifting in hepatitis C virus infection testing and treatment: a global systematic review and meta-analysis","volume":"9","author":"Oru","year":"2021","journal-title":"Lancet Glob. Health"},{"issue":"2","key":"10.1016\/j.drugalcdep.2025.113014_bib31","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/jvh.13214","article-title":"Improving access to care for people who inject drugs: qualitative evaluation of project ITTREAT-An integrated community hepatitis C service","volume":"27","author":"Phillips","year":"2020","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.drugalcdep.2025.113014_bib32","article-title":"IDPC briefing paper the Dutch treatment and social support system for drug users","author":"Schatz","year":"2011","journal-title":"Int. Drug Policy Consort."},{"issue":"10207","key":"10.1016\/j.drugalcdep.2025.113014_bib33","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(19)32320-7","article-title":"Hepatitis C","volume":"394","author":"Spearman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.drugalcdep.2025.113014_bib34","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/1748-5908-9-74","article-title":"Operationalizing the RE-AIM framework to evaluate the impact of multi-sector partnerships","volume":"9","author":"Sweet","year":"2014","journal-title":"Implement Sci."},{"key":"10.1016\/j.drugalcdep.2025.113014_bib35","unstructured":"Trimbos. 2017. Blueprint \u2013 Hepatitis C care pathway for clients in addiction care."},{"issue":"1","key":"10.1016\/j.drugalcdep.2025.113014_bib36","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13722-021-00260-8","article-title":"'Treat my whole person, not just my condition': qualitative explorations of hepatitis C care delivery preferences among people who inject drugs","volume":"16","author":"Tsui","year":"2021","journal-title":"Addict. Sci. Clin. Pract."},{"issue":"9","key":"10.1016\/j.drugalcdep.2025.113014_bib37","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1111\/j.1360-0443.2007.01912.x","article-title":"Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users","volume":"102","author":"Van Den Berg","year":"2007","journal-title":"Addiction"},{"key":"10.1016\/j.drugalcdep.2025.113014_bib38","unstructured":"VKN. 2025. Retrieved 03-04-2025 from \u3008https:\/\/verslavingskundenederland.nl\/we-are-daa\/\u3009"},{"issue":"4","key":"10.1016\/j.drugalcdep.2025.113014_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11041146","article-title":"Against all odds? Addiction history associated with better viral hepatitis care: a Dutch nationwide claims data study","volume":"11","author":"Von den Hoff","year":"2022","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.drugalcdep.2025.113014_bib40","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13722-022-00350-1","article-title":"Implementation of a decentralized hepatitis C care pathway for people who use drugs in Dutch addiction care. Study protocol for the Hepatitis C: chain of addiction care (CAC) project","volume":"17","author":"Von den Hoff","year":"2022","journal-title":"Addict. Sci. Clin. Pract."},{"key":"10.1016\/j.drugalcdep.2025.113014_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2025.112759","article-title":"Facilitators and barriers for implementation of a decentralized hepatitis C care chain for people who use drugs in Dutch addiction care","volume":"274","author":"Von den Hoff","year":"2025","journal-title":"Drug Alcohol Depend."},{"issue":"9","key":"10.1016\/j.drugalcdep.2025.113014_bib42","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1093\/cid\/ciz546","article-title":"Outcomes of treatment for hepatitis C in primary care, compared to hospital-based care: a randomized, controlled trial in people who inject drugs","volume":"70","author":"Wade","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.drugalcdep.2025.113014_bib43","unstructured":"WHO. 2022. Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022-2030."},{"key":"10.1016\/j.drugalcdep.2025.113014_bib44","unstructured":"WHO. 2024. Implementing the global health sector strategies on HIV, viral hepatitis and sexually transmitted infections, 2022\u20132030: report on progress and gaps 2024, second edition."},{"issue":"2","key":"10.1016\/j.drugalcdep.2025.113014_bib45","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s12072-023-10609-7","article-title":"An algorithm for simplified hepatitis C virus treatment with non-specialist care based on nation-wide data from Taiwan","volume":"18","author":"Yu","year":"2024","journal-title":"Hepatol. Int."}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871625004673?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871625004673?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T16:15:13Z","timestamp":1777565713000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871625004673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":45,"alternative-id":["S0376871625004673"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2025.113014","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Successful hepatitis C elimination through decentralized treatment in Dutch addiction care: A RE-AIM based evaluation","name":"articletitle","label":"Article Title"},{"value":"Drug and Alcohol Dependence","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2025.113014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"113014"}}